Tina Smith sold Medtronic PLC (NYSE: MDT)
Tina Smith (D-MN), a U.S. Senator, has disclosed 1 trade in Medtronic PLC (MDT) since 2023, a single sale, worth an estimated $175K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a sale: Tina Smith sold $100,001 - $250,000 of Medtronic PLC (NYSE: MDT) on April 5, 2023. Since that trade, MDT is up +17.71% against the S&P 500 up +89.10%, an outperformance of -71.39%.
Data updated
Tina Smith's MDT trades vs the price
MDT is up +17.71% since Tina Smith sold on April 5, 2023, versus +89.10% for the S&P 500.
Performance since this trade
All Tina Smith MDT trades
Tina Smith & MDT trading FAQ
Is it legal for Tina Smith to trade Medtronic PLC (MDT) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Medtronic PLC (MDT), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Tina Smith sell MDT?
Tina Smith disclosed a sale of $100,001 - $250,000 of Medtronic PLC (MDT) on April 5, 2023, according to public STOCK Act filings.
How has MDT performed since Tina Smith's trade?
Since Tina Smith sold MDT on April 5, 2023, the stock is up +17.71%, versus +89.10% for the S&P 500 over the same period, an outperformance of -71.39%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional MDT trades?
Quantellect tracks every disclosed congressional trade in Medtronic PLC (MDT) on the Medtronic PLC congressional trading page, which aggregates filings across all members of Congress.
Tina Smith's MDT tradesAll congressional filings for Medtronic PLCTina Smith's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.